Cartesian Therapeutics, Inc. - COMMON STOCK (RNAC)

Historical Holders from Q1 2023 to Q3 2025

Symbol
RNAC on Nasdaq
Type / Class
Equity / COMMON STOCK
Shares outstanding
25,973,289
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
5,968,086
Holdings value
$60,898,831
% of all portfolios
0%
Number of holders
65
Number of buys
26
Number of sells
24
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Cartesian Therapeutics, Inc. - COMMON STOCK (RNAC) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
SPRINGER TIMOTHY A 37% +0.27% $101,956,054 +$225,969 9,555,394 +0.22% Timothy A. Springer 13 Jan 2025
FMR LLC 8.3% -12% $22,041,372 -$2,734,285 2,155,783 -11% FMR LLC 30 Sep 2025
JPMORGAN CHASE & CO 6.1% $17,879,036 1,675,636 JPMORGAN CHASE & CO. 31 Mar 2025
As of 30 Sep 2025 Cartesian Therapeutics, Inc. - COMMON STOCK (RNAC) has 65 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 5,968,086 shares of 25,973,289 outstanding shares and own 23% of the company stock as of 30 Sep 2025.

Top 25 institutional shareholders of Cartesian Therapeutics, Inc. - COMMON STOCK (RNAC) own 22% of the company based on 13F filings as of 30 Sep 2025

Filer Ownership Holdings Value Nb Shares Share Change %
FMR LLC 8.3% $22,032,103 2,155,783 -7.6%
BlackRock, Inc. 2.5% $6,636,266 649,341 -0.69%
Siren, L.L.C. 2.2% $5,756,640 563,272 0%
VANGUARD GROUP INC 2% $5,321,779 520,722 +4.9%
MPM BIOIMPACT LLC 1.5% $3,883,600 380,000 -45%
Erste Asset Management GmbH 1% $2,561,108 260,011 0%
GEODE CAPITAL MANAGEMENT, LLC 0.93% $2,471,880 241,829 +10%
683 Capital Management, LLC 0.89% $2,350,601 230,000 +5%
STATE STREET CORP 0.76% $2,020,147 197,666 +1.7%
NORTHERN TRUST CORP 0.35% $932,974 91,289 +10%
GSA CAPITAL PARTNERS LLP 0.33% $880,000 86,095 +107%
MARSHALL WACE, LLP 0.33% $866,718 84,806 +2.6%
CITADEL ADVISORS LLC 0.27% $720,756 70,524 -42%
ROYAL BANK OF CANADA 0.14% $370,000 36,222 +98%
JACOBS LEVY EQUITY MANAGEMENT, INC 0.12% $306,610 30,001 -27%
Freestone Capital Holdings, LLC 0.1% $264,913 25,921 0%
MILLENNIUM MANAGEMENT LLC 0.1% $259,149 25,357
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.1% $255,500 25,000
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.1% $254,427 24,895 -0.03%
Nuveen, LLC 0.09% $250,359 24,497 0%
Bank of New York Mellon Corp 0.09% $247,231 24,191 -3.2%
Ikarian Capital, LLC 0.09% $226,537 22,166 0%
TWIN FOCUS CAPITAL PARTNERS, LLC 0.08% $199,290 19,500 +2.6%
MORGAN STANLEY 0.07% $193,914 18,974 -35%
BARCLAYS PLC 0.07% $182,346 17,842 -42%

Institutional Holders of Cartesian Therapeutics, Inc. - COMMON STOCK (RNAC) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 5,968,086 $60,898,831 -$4,440,061 $10.22 65
2025 Q2 6,401,037 $66,468,780 -$2,049,026 $10.39 65
2025 Q1 6,582,077 $86,709,744 -$755,344 $13.18 68
2024 Q4 6,665,629 $119,475,582 -$2,695,276 $17.91 63
2024 Q3 6,867,968 $110,349,122 +$42,879,899 $16.12 61
2024 Q2 3,271,748 $88,277,281 +$88,060,120 $27.01 59
2024 Q1 1,855 $1,157 +$1,157 $0.6375 4
2023 Q4 0 $0 -$1,272 0
2023 Q3 1,200 $1,272 $0 $1.06 1
2023 Q2 1,200 $1,344 $0 $1.12 1
2023 Q1 1,200 $1,668 $0 $1.39 1